How should a cisplatin dose of 70 mg/m² be administered, including required dilution, infusion duration, and choice of peripheral versus central venous access?

Administration of Cisplatin 70 mg/m²

Cisplatin 70 mg/m² should be administered via slow intravenous infusion over 6-8 hours in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol, with mandatory pretreatment hydration of 1-2 liters over 8-12 hours, and can be safely given through peripheral venous access in large forearm veins using flexible cannulae. 1

Dilution and Infusion Protocol

The FDA-approved preparation requires:

• Dilution volume: 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline
• Add: 37.5 g of mannitol to the dilution
• Infusion duration: 6-8 hours (never rapid IV injection)
• Pretreatment hydration: 1-2 liters of fluid over 8-12 hours before cisplatin
• Post-treatment: Maintain adequate hydration and urinary output for 24 hours after infusion 1

Critical preparation note: Do not dilute cisplatin in 5% Dextrose alone. Never use aluminum-containing needles or IV sets, as aluminum reacts with cisplatin causing precipitate formation and loss of potency 1.

Venous Access Selection

Peripheral Access is Appropriate

For a 70 mg/m² dose, peripheral IV access is acceptable and may be preferred based on the following evidence:

• The 70 mg/m² dose falls within the FDA-approved range for bladder cancer (50-70 mg/m²) 1
• Research demonstrates safe outpatient administration of cisplatin 70-90 mg/m² through peripheral access with acceptable tolerance 2
• A 2024 study in testicular cancer patients showed peripheral IV had significantly lower complication rates (9.7% transition rate) compared to central venous access devices (52.2% venous access-related complications, 35.9% thrombotic events) 3

When to Use Peripheral Access

Use large veins in the forearm with these specifications 4:

• Flexible cannulae (never steel "butterfly" needles for vesicant drugs)
• Avoid anticubital fossa, dorsum of hand, joints, inner wrist, and lower extremities
• Avoid areas with lymphedema or on the side of mastectomy
• Ensure blood return before and regularly during infusion
• Monitor continuously for swelling, pain, redness, or sluggish infusion

When Central Access is Mandatory

Central venous access device (CVAD) is highly recommended for 4:

• Infusions of vesicant drugs lasting 12-24 hours or longer
• Patients with difficult venous access (small/fragile/sclerosed veins)
• Conditions with impaired circulation (Raynaud syndrome, advanced diabetes, severe peripheral vascular disease)
• Obesity where peripheral access is difficult

Extravasation Risk Management

Cisplatin is classified as a vesicant agent. The concentration after dilution (70 mg/m² in 2 liters ≈ 0.035 mg/mL for average patient) is well below the 0.5 mg/mL threshold associated with severe tissue toxicity 1. However:

• Obtain blood return before administration and check regularly throughout infusion
• Flush with 10-20 mL saline between drug infusions
• Monitor insertion site continuously for tingling, burning, discomfort, swelling, or redness
• Local tissue toxicity severity relates to cisplatin concentration; infusions >0.5 mg/mL may cause cellulitis, fibrosis, necrosis 1

Common Pitfalls to Avoid

1. Aluminum exposure: Verify all equipment is aluminum-free to prevent precipitate formation 1
2. Inadequate hydration: Insufficient pre/post-hydration increases nephrotoxicity risk
3. Rapid infusion: Never give as bolus or rapid injection—must be 6-8 hour infusion 1
4. Wrong diluent: Using 5% Dextrose alone is contraindicated 1
5. Butterfly needles: Steel needles can easily displace and puncture venous walls with vesicants 4
6. Concentration >0.5 mg/mL: Higher concentrations significantly increase extravasation injury severity 1

Safety Monitoring Requirements

Before each cycle, verify:

• Serum creatinine <1.5 mg/100 mL
• BUN <25 mg/100 mL
• Platelets ≥100,000/mm³
• WBC ≥4,000/mm³
• Audiometric analysis showing normal auditory acuity 1

The 70 mg/m² dose represents a moderate-intensity regimen with research showing only 13.9% decrease in calculated creatinine clearance between cycles 1 and 6, with acceptable tolerance in outpatient settings 2.